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1. Introduction 
2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720, fingolimod 
hydrochloride) is an orally active sphingosine 1-phosphate (S1P) receptor modulator with a 
structure closely related to sphingosine (Adachi et al., 1995; Chiba et al., 1996, 1997) (Fig. 1). 
FTY720 sequesters circulating mature lymphocytes into the secondary lymphoid organs 
(SLO) and thymus by long-term down-regulation of S1P receptor type 1 (S1P1) on 
lymphocytes, and shows potent immunomodulating effects (Brinkmann et al., 2000, 2002a, 
2002b, 2004; Chiba et al., 1998, 1999, Chiba, 2005; Matloubian et al., 2004).  
It has been previously reported that a potent immunosuppressive natural product, myriocin 
(ISP-I) can be isolated from a culture broth of Isaria scinclairii, a kind of vegetative wasp 
(Fujita et al., 1994a, 1994b; Sasaki et al.,1994). The chemical modification of ISP-I led to a 
novel synthetic compound, FTY720 that has more potent immunomodulating activity and 
less toxicity than myriocin (Adachi et al., 1995; Fujita et al., 1995, 1996; Kiuchi et al., 2000). 
FTY720 is highly effective in prolonging allograft survival in various experimental allograft 
models (Chiba et al., 1996, 1998, 2005; Hoshino et al., 1996; Kawaguchi et al., 1996; 
Masubuchi et al., 1996; Suzuki et al., 1996, 1998). A striking feature of FTY720 is the 
induction of a marked decrease in the number of peripheral blood lymphocytes (T cells and 
B cells) at doses that prolong allograft survival (Chiba et al., 1996, 1998, 1999; Yanagawa et 
al., 1998a, 1998b, 1999, 2000). The reduction of the number of peripheral blood lymphocytes 
induced by FTY720 is mainly caused by sequestration of circulating mature lymphocytes 
into the SLO as lymph nodes and Peyer’s patches (Chiba et al., 1998, 1999, Yanagawa et al., 
1998a, 1998b). 
It has been reported that FTY720 is effectively phosphorylated to FTY720-phosphate 
(FTY720-P, (S)-enantiomer) (Fig. 1) by sphingosine kinases (Billich et al., 2003; Paugh et al., 
2003) and that FTY720-P is a high affinity agonist at four types of S1P receptors (S1P1, S1P3, 
S1P4, and S1P5) (Brinkmann et al., 2002a, 2002b; Mandala et al., 2002). It is well documented 
that S1P1 plays an essential role in lymphocyte egress from the SLO to lymph (Brinkmann et 
al., 2004; Chiba, 2005; Matloubian et al., 2004). FTY720-P induces a long-lasting 
internalization and degradation of S1P1, reduces S1P responsiveness of lymphocytes, and 
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inhibits lymphocyte egress from the SLO (Brinkmann et al 2002a, 2004; Chiba, 2005; Cyster, 
2005; Graler et al., 2004, Maeda et al., 2007, Matloubian et al., 2004; Pham et al., 2008). 
Consequently, FTY720-P acts as a functional antagonist at lymphocytic S1P1 and 
immunomodulating effects of FTY720 are likely due to inhibition of egress of antigen-
specific T cells from draining lymph nodes. 
 
 
Fig. 1. The Chemical structures of myriocin (ISP-I), sphingosine, sphingosine 1-phospahete 
(S1P), fingolimod (FTY720) and FTY720-phosphate (FTY720-P). 
Multiple sclerosis (MS) is a common and often disabling disease of the central nervous 
system (CNS). Early active MS lesions are characterized by the presence of infiltrated 
mononuclear cells around venules and small veins, followed by myelin breakdown and 
astrogliosis, resulting in irreversible disability (Lubin et al., 1996; Martin et al., 1992; 
Rammohan, 2003). The etiology of MS remains unknown, but is widely considered to 
involve the organ-specific autoimmune destruction of CNS myelin mediated by myelin-
specific T cells (Anderson et al., 2004; Seamons et al., 2003). Immunomodulating therapy 
using cyclophosphamide, interferon (IFN)-ǃ, or glatiramer acetate is widely used for the 
treatment of MS (Goodkin et al., 1999; Zamvil et al., 2003). Experimental autoimmune 
encephalomyelitis (EAE), an animal model of human MS, is a demyelinating, inflammatory 
disease of the CNS and is induced by the immunization of susceptible strains of rats or mice 
with myelin antigens combined with adjuvant (Kuchroo et al., 1993; Martin et al., 1992, 1995; 
Owens et al., 1995). It is highly likely that trafficking and infiltration of IFN-Ǆ-expressing 
type 1 helper T cells (Th1 cells) (Bright et al., 1998; Merrill et al., 1992; Windhagen et al., 
1995) and interleukin 17 (IL-17)-expressing helper T cells (Th17 cells) (Bettelli et al., 2006; 
Komiyama et al., 2006; Kroenke et al., 2008; Langrish et al., 2005; Steinman, 2010; Stromnes 
et al., 2008) into the CNS play an important role in the development and progression of EAE 
because myelin antigen-specific Th17 cells and Th1 cells can be found in the blood, 
lymphoid tissues and CNS in EAE and MS. 
There are several reports on ameliorating effects of FTY720 on EAE in mice and rats 
(Balatoni et al., 2007; Brinkmann et al., 2002a; Chiba et al., 2011; Foster et al., 2007; Fujino et 
al., 2003; Kataoka et al., 2005; Webb et al., 2004). In myelin basic protein (MBP)-induced EAE 
in LEW rats, prophylactic administration of FTY720 at 0.1 to 1 mg/kg almost completely 
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prevents the development of EAE symptoms and EAE-associated histological change in the 
spinal cords (Fujino et al., 2003; Kataoka et al. 2005). In myelin oligodendrocyte glycoprotein 
(MOG)-induced EAE in DA rats, prophylactic therapy of FTY720 protects against the 
emergence of EAE symptoms, neuropathology, and disturbances to visual and 
somatosensory evoked potentials (Foster et al., 2007, Balatoni et al., 2007). Consistent with 
rat EAE, development of EAE induced by myelin proteolipid protein (PLP) in SJL/J mice is 
almost completely prevented and infiltration of CD4 T cells into spinal cord is decreased by 
prophylactic treatment with FTY720 and FTY720-P (Webb et al., 2004; Kataoka et al., 2005). 
When FTY720 or FTY720-P is given after establishment of EAE in SJL/J mice, marked 
therapeutic effects on EAE are observed accompanying with reduction of demyelination and 
infiltration of CD4 T cells in the spinal cords (Chiba et al., 2011; Kataoka et al., 2005; Webb et 
al., 2004). Similar therapeutic effects by FTY720 are obtained in MOG-induced EAE in 
C57BL/6 mice (Chiba et al., 2011; Kataoka et al., 2005, Seki et al., 2010). 
In this chapter, we demonstrate the prophylactic and therapeutic effects of FTY720 on EAE 
in rats and mice using MBP, myelin PLP or MOG as myelin antigens (Chiba et al., 2011; 
Kataoka et al., 2005, Seki et al., 2010). Our findings suggest that FTY720 is more efficacious 
in mouse EAE as compared with rm-IFN-ǃ and that the ameliorating effects of FTY720 on 
EAE are likely due to reduction of the infiltration of myelin antigen-specific Th17 and Th1 
cells into the CNS.  
On the other hand, it has been well documented that neural cells express S1P receptors and 
FTY720 can distribute into the CNS beyond blood brain barrier (Brinkmann, 2009). Recently, 
it has been strongly suggested that FTY720-P directly acts as a functional antagonist at S1P1 
on not only lymphocytes but also neural cells, particularly astrocytes because the 
therapeutic effects of FTY720 on EAE was lost in CNS mutants lacking S1P1 on astrocytes 
but not neuron (Choi et al, 2011). Since FTY720 possesses a completely new mechanism of 
action, FTY720 should provide a useful therapeutic approach for MS. 
2. Discovery of FTY720 from a natural product, myriocin  
A potent immunosuppressive natural product, myriocin was isolated from a culture broth 
of Isaria sinclairii, a kind of vegetative wasp that is an "eternal youth" nostrum in traditional 
Chinese herbal medicine (Fujita et al., 1994a, 1994b; Sasaki et al., 1994). Chemical 
modification of myriocin yielded a new compound, FTY720 (Fig. 1), which has more potent 
immunomodulating activity and less toxicity than myriocin (Adachi et al., 1995; Fujita et al., 
1995, 1996; Kiuchi et al., 2000). FTY720 at an oral dose of 0.1 mg/kg or higher significantly 
prolongs allograft survival in experimental skin, cardiac and renal allotransplantation 
models (Chiba et al., 1996, 1997, 1998; Hoshino et al., 1996; Kawaguchi et al., 1996; 
Masubuchi et al., 1996; Suzuki et al., 1996, 1998). Unlike calcineurin inhibitors, FTY720 does 
not impair lymphocyte function including T cell activation and production of Th1 cell-
associated cytokines by antigen stimulation (Chiba et al., 1996, 1997, 1998; Yanagawa et al., 
1998a). Moreover, we have demonstrated that FTY720 does not inhibit serine 
palmitoyltransferase that is the first enzyme in sphingolipid biosynthesis and is the target 
enzyme of myriocin (Fujita et al., 1996).  
A striking feature of FTY720 is the induction of a marked decrease in the number of 
peripheral blood lymphocytes at doses that display an immunomodulating activity (Chiba 
et al., 1996, 1997, 1998, Li et al., 2002; Yagi et al., 2000; Yanagawa et al., 1998a, 1998b). In rats, 
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the number of lymphocytes (T cells and B cells) in peripheral blood decreases dramatically 
within 6 hours after oral administration of FTY720 at 0.1 to 1 mg/kg (Chiba et al., 1998, 
1999). To clarify the mechanism of lymphocyte reduction by FTY720, distribution of 
lymphocytes in blood, lymph, and various SLO was analyzed after FTY720 administration 
in rats (Chiba et al., 1998). When FTY720 at an oral dose of 0.1 mg/kg or higher is given to 
rats or mice, the number of lymphocytes is decreased markedly in the peripheral blood and 
thoracic duct lymph whereas that in the SLO is increased significantly. Intravenous 
transfusion of fluorescein-labelled lymphocytes into rats reveals that the labelled 
lymphocytes are accumulated in the SLO by FTY720 administration (Chiba et al, 1998). 
These data suggest that FTY720 induces sequestration of circulating mature lymphocytes 
into SLO and decreases the number of lymphocytes in peripheral blood, and lymph. Thus, 
sequestration of circulating mature lymphocytes is presumed to be the main mechanism of 
immunomodulating activity of FTY720. As reported previously, immunohistochemical 
staining and flow cytomeric analysis revealed that FTY720 decreases the infiltration of T 
cells into the allograft at doses showing immunomodulating effects (Chiba, 2005, Yanagawa 
et al, 1998a, 1999, 2000). These findings strongly suggest that FTY720 exerts 
immunomodulating activity by decreasing T cell infiltration into inflammatory sites. 
3. Mechanism of action of FTY720, S1P receptor modulator 
Circulation of mature lymphocytes among the SLO, lymph and blood plays a central role in 
the establishment of the immune response to foreign antigens. Homing of lymphocytes from 
blood into the SLO beyond high endothelial venules is highly dependent on the interaction 
between the CC-chemokine ligand (CCL) 19, CCL21, CXC-chemokine ligand (CXCL) 13, and 
their receptors: CC-chemokine receptor (CCR) 7 and CXC-chemokine receptor (CXCR) 5 on 
lymphocytes. On the other hand, throughout the analyses of the mechanism of action of 
FTY720, it is clarified that S1P and its receptor, S1P1 play an essential role in lymphocyte 
egress from the SLO to lymph (Brinkmann et al 2002a, 2004; Chiba, 2005; Chiba et al., 2006; 
Cyster, 2005; Lo et al., 2005; Maeda et al., 2007, Matloubian et al., 2004; Pham et al., 2008). 
Reverse pharmacological approaches have been performed to elucidate that FTY720 is 
phosphorylated by sphingosine kinases (Billich et al., 2003; Paugh et al., 2003) and FTY720-
phosphate (FTY720-P) acts as a high affinity agonist of 4 types of S1P receptors (S1P1, S1P3, 
S1P4, and S1P5) (Brinkmann et al, 2002a, 2002b; Mandala et al., 2002). After oral or 
intravenous FTY720 administration, the plasma concentration of FTY720-P was 2 to 6 times 
higher than FTY720 (Brinkmann et al 2002a).  
S1P, a pleiotropic lysophospholipid mediator is converted primarily by the phosphorylation 
of sphingosine by sphingosine kinases and stimulates multiple signalling pathways 
resulting in calcium mobilization from intracellular stores, polymerization of actin, 
chemotaxis/migration, and escape from apoptosis (Hla et al., 2001, Pyne et al.; 2000). S1P is 
predominantly released by red blood cells or platelets and is found in significant amounts 
(100 to 400 nM) in serum (Kimura et al, 2001). S1P binds with nano-molar affinities to five 
related G-protein-coupled receptors, termed S1P1-5 (Brinkmann et al., 2002a, 2002b; Chiba, 
2005; Mandala et al. 2002) (Fig. 2). It has been reported that S1P1 is essential for lymphocyte 
recirculation and that S1P1 regulates lymphocyte egress from the SLO (Brinkmann et al 
2002, 2004; Chiba, 2005; Cyster, 2005; Maeda et al., 2007, Matloubian et al., 2004; Pham et al., 
2008). In mice whose hematopoietic cells lack a single S1P receptor, S1P1, there are no T cells 
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in the periphery because mature T cells are unable to exit SLO (Matloubian et al., 2004). 
Moreover, S1P1-dependent chemotactic responsiveness is suggested to be up-regulated in 
lymphocytes before exit from the SLO, whereas S1P1 is down-regulated during peripheral 
lymphocyte activation, and this is associated with retention of lymphocytes in the SLO (Lo 
et al, 2005).  
 
 
Fig. 2. Generation of S1P and interaction with S1P receptor. S1P is generated primarily by 
the phosphorylation of intracellular sphingosine by sphingosine kinases and binds to five 
related G-protein-coupled S1P receptors (S1P1-5). 
FTY720 treatment down-regulates S1P1, creating a temporary pharmacological S1P1-null 
state in lymphocytes, providing an explanation for the mechanism of FTY720-induced 
lymphocyte sequestration (Graler et al., 2004; Matloubian et al., 2004). Since S1P1 surface 
expression on lymphocytes is highly dependent on the extracellular concentration of S1P, 
S1P1 on lymphocytes is down-regulated in the blood, up-regulated in SLO and down-
regulated again in the lymph (Cyster, 2005; Lo et al., 2005). Thus, it is proposed that cyclical 
modulation of S1P1 surface expression on circulating lymphocytes by S1P contributes to 
establishing their transit time in SLO. 
We have confirmed that only the (S)-enantiomer of FTY720-P can bind to four types of S1P 
receptors (S1P1, 3, 4, 5) at nano-molar concentrations, but not S1P2, whereas FTY720 up to 
10,000 nM does not bind S1P receptors (Chiba, 2005, Kiuchi et al., 2005). FTY720-P shows 
agonist activity for S1P1 at nano-molar concentrations using extracellular signal regulated 
kinase 1/2 (ERK1/2) phosphorylation assay and subsequently induces long-term 
internalization of S1P1 in Chinese hamster ovary (CHO) cells stably expressing human S1P1 
(Chiba, 2005; Chiba et al.; 2006, Maeda et al., 2007). The internalization of S1P1 by FTY720-P 
appears to be maintained longer than that by S1P and the difference between FTY720-P and 
S1P seems to be due to the distinct stability of FTY720-P and S1P for degradation by S1P 
lyase. S1P at concentrations of 10 to 100 nM induces migration of lymph node CD4+ T cells 
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in mice. By contrast, the pretreatment with FTY720-P effectively inhibits the migration of 
CD4+ T cells toward S1P (Chiba, 2005; Chiba et al.; 2006, Maeda et al., 2007). Based on these 
results, it is presumed that FTY720-P converted from FTY720 acts as a functional antagonist 
at S1P1 receptor by internalization and degradation of the S1P1, reduces S1P responsiveness 
of lymphocytes, and inhibits S1P1-dependent lymphocyte egress from SLO (Fig. 3). 
 
 
 
Fig. 3. FTY720-P converted from FTY720 inhibits S1P/S1P1 axis-dependent lymphocyte 
egress from SLO by functional antagonism (internalization and degradation) at lymphocytic 
S1P1. 
4. Effects of FTY720 on MBP-induced EAE in LEW rats 
We examined the prophylactic and therapeutic effects of FTY720 on EAE induced by 
immunization with MBP in LEW rats (Kataoka et al., 2005). All of the LEW rats in the 
vehicle-treated control group developed EAE-associated clinical symptoms 10 days after 
immunization with guinea pig MBP, reaching a maximal level on day 13 followed by a 
gradual decline (Fig. 4A). Elevation of EAE scores was significantly inhibited in groups 
given FTY720 prophylactically at oral doses of 0.1, 0.3, and 1 mg/kg for 20 days from the 
day of MBP immunization. Consistent with EAE-associated symptoms, the histological 
scores in FTY720-treated groups decreased significantly and dose-dependently as compared 
with the vehicle-treated control group. 
To evaluate the therapeutic potential of FTY720 in MBP-induced EAE in LEW rats, the 
administration was started from the day of EAE onset (Fig. 4B). In the vehicle-treated 
control group, EAE had developed by day 9 after immunization and reached a maximal 
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level on day 11 to 13. Thereafter, the mean of EAE scores remained within the 2 to 3 range 
until day 20, because 4 out of 8 EAE rats died with severe symptoms in the control group. 
Therapeutic administration of FTY720 from the day of EAE onset significantly decreased 
post-peak EAE-associated clinical signs. Moreover, the therapeutic administration of FTY720 
resulted in a significant decrease in the histological score of EAE. The infiltration of 
inflammatory cells into the spinal cords of EAE rats was inhibited in the FTY720-treated 
group. These data indicate that FTY720 not only has a prophylactic but also a therapeutic 
potential in MBP-induced EAE in LEW rats. 
 
 
 
Fig. 4. Prophylactic and therapeutic effects of FTY720 on MBP-induced EAE in LEW rats. 
LEW rats were immunized with guinea pig MBP (100 μg/rat) and Freund’s complete 
adjuvant. FTY720 was administered orally to MPB-immunized LEW rats every day from the 
day of immunization (A: prophylactic administration) or the day of onset (B: therapeutic 
administration) until day 20. Rats in the control group were administered vehicle only. The 
results are expressed as the mean ± S.E.M of 8 animals and statistical differences were 
calculated by Steel’s test (non-parametric Dunnett’s multiple comparison test, *: 
p<0.05, **: p<0.01). 
5. Effects of FTY720 on PLP-induced EAE in SJL/J mice 
5.1 Prophylactic effects of FTY720 on PLP-induced EAE in SJL/J mice 
In human MS, neurological symptoms relapse over several years; however MPB-induced EAE 
in LEW rats was monophasic with no relapse. To clarify the therapeutic potential of FTY720 in 
human MS more precisely, we evaluated the effect of FTY720 and its active metabolite, 
FTY720-P on relapsing EAE in SJL/J mice induced by PLP139–151 immunization (Chiba et al., 
2011; Kataoka et al., 2005). SJL/J mice immunized with PLP139–151 emulsified in Freund’s 
complete adjuvant resulted in the development of EAE-associated clinical symptoms and a 
decrease in body weight 11 days after immunization. EAE scores rapidly elevated and reached 
a maximal level on day 15. The first phase of EAE remitted with a low EAE score on day 20 
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and spontaneously relapsed thereafter (Fig. 5A). The elevation of EAE-associated clinical score 
and the loss of body weight were prevented in groups given FTY720 prophylactically at oral 
doses of 0.1 and 0.3 mg/kg for 42 days from the day of immunization (Figs. 5). Consistent with 
MBP-induced EAE in LEW rats, there was no increase in EAE score in the group treated with 
FTY720 at 1 mg/kg, indicating a complete prevention of PLP139–151-induced EAE in SJL/J mice 
(Kataoka et al., 2005).  Almost the same prophylactic effect was observed when FTY720-P at 0.1 
and 1 mg/kg was administered intraperitoneally to PLP139–151-immunized SJL/J mice from the 
day of immunization. By contrast, prophylactic treatment with recombinant mouse (rm)-IFN-ǃ 
at 10000 IU three times a week intraperitoneally showed no clear effect or no lymphopenia 
(Kataoka et al., 2005).  
The infiltration of inflammatory cells was observed in the spinal cord of SJL/J mice 17 days 
after immunization with PLP139–151 (Kataoka et al., 2005). Prophylactic administration of 
FTY720 at 1 mg/kg orally resulted in a marked reduction of the infiltration of inflammatory 
cells in the spinal cord of PLP139–151-immunized SJL/J mice (Fig. 6A-D). Immunohisto-
chemical staining analysis using anti-T cell subset mAbs revealed the infiltration of CD4+ T  
cells rather than CD8+ T cells into the spinal cord, especially the perivascular area and 
funiculus dorsalis in white matter under pia mater, of PLP139–151-immunized SJL/J mice with 
developed EAE. Prophylactic administration of FTY720 at 1 mg/kg orally markedly 
decreased the infiltration of CD4+ T cells into the spinal cord as compared with the vehicle-
treated control EAE group (Fig. 6E-H). 
 
 
 
Fig. 5. Prophylactic effect of FTY720 on PLP139-151-induced EAE in SJL/J mice. SJL/J mice 
were immunized with PLP139-151 (50 μg/mouse) and Freund’s complete adjuvant. FTY720 
was administered orally to PLP139-151-immunized SJL/J mice every day from the day of 
immunization for 42 days. Mice in the control groups were administered vehicle only. The 
results are expressed as the mean ± S.E.M. of 7 animals and statistical differences in clinical 
scores of EAE were calculated by Steel’s test (*: p<0.05, **: p<0.01). 
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Fig. 6. Prophylactic administration of FTY720 decreased the infiltration of CD4+ T cells into 
the spinal cord of EAE mice induced by PLP139-151 immunization. SJL/J mice were 
immunized with PLP139-151 and administered FTY720 at 1 mg/kg p.o. prophylactically. On 
day 17 after immunization, the spinal cords of EAE-developed mice were obtained, and 
haematoxylin and eosin (H&E) and immunohistochemical staining with anti mouse CD4 
monoclonal antibody (mAb) were performed.  
5.2 Therapeutic effects of FTY720 on PLP-induced EAE in SJL/J mice 
To evaluate the therapeutic effect of FTY720 on PLP139–151-induced, relapsing EAE in SJL/J 
mice, EAE-developed mice were pooled, divided into 4 groups consisting of six mice, and 
administration of FY720 was started 17 days after immunization (Kataoka et al., 2005). EAE-
associated clinical signs had decreased rapidly by day 21, and thereafter, relapse of EAE 
occurred in the vehicle-treated control group (Fig. 7A). By contrast, the relapse of EAE was 
markedly inhibited and no EAE-associated clinical signs were observed from day 32 to 59 in 
groups given FTY720 at 0.3 and 1 mg/kg therapeutically, indicating complete inhibition of 
EAE relapse. In the group given rm-IFN-ǃ at 10000 IU three times a week intraperitoneally, 
the EAE score was significantly lowered at day 24, and relapse was delayed; however rm-
IFN-ǃ failed to inhibit the relapse of EAE. In another experiment, it was confirmed that the 
magnitude of the therapeutic effect of FTY720 is almost equal to that of prednisolone (1 
mg/kg p.o.) (Fig. 7B). In the group given FTY720 at 1 mg/kg therapeutically, the area of 
demyelination and the infiltration of CD4+ T cells into the spinal cord were decreased as 
compared with the vehicle-treated control group (Fig. 8). Similarly, the relapse of EAE was 
markedly inhibited in groups given FTY720-P at 0.1 and 1 mg/kg therapeutically (Kataoka 
et al., 2005). 
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Fig. 7. Therapeutic effect of FTY720 on PLP139-151-induced EAE in SJL/J mice. SJL/J mice 
were immunized with PLP139-151 (50 μg/mouse) and Freund’s complete adjuvant. EAE-
developed mice were pooled, divided into 4 groups and administrations of FTY720 (daily), 
rm-IFN-ǃ (3 times a week), and prednisolone (daily) were started from day 17. The results 
are expressed as the mean ± S.E.M of 7 animals and statistical differences in clinical scores of 
FTY720 groups were calculated by Steel’s test (*: p<0.05, **: p<0.01), and those in rm-IFN-ǃ 
or prednisolone were done by Mann Whitney U test (#: p<0.05). 
 
Fig. 8. Therapeutic administration of FTY720 decreased infiltration of CD4+ T cells into 
spinal cords of PLP139-151-induced EAE mice. SJL/J mice were immunized with PLP139-151 and 
were administered FTY720 (1 mg/kg p.o.) therapeutically from day 17. The spinal cords of 
EAE-developed mice were obtained on day 28, and were performed immunohistochemical 
staining with anti-mouse CD4 mAb. 
5.3 FTY720 shows a superior efficacy as compared with IFN-β in the relapse of EAE 
induced by PLP in SJL/J mice 
To clarify the preventing effects of FTY720 on relapse of EAE induced by PLP139–151 in SJL/J 
mice, EAE-developed mice were pooled on day 15 after immunization, divided into 5 
groups, and administered vehicle or FTY720 (oral doses of 0.03, 0.1, 0.3 and 1 mg/kg) daily 
for 28 days (Fig. 9A) (Chiba et al., 2011). In vehicle-treated control group, the first phase of 
EAE was remitted with low EAE scores by day 8 after primary administration; however 
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EAE symptoms were relapsed on day 10 to day 14 spontaneously, reached to maximal level 
on day 16, and maintained with high severity thereafter. The relapse of EAE was 
significantly inhibited in all of FTY720 groups and no clinical symptoms were observed in 
the groups given FTY720 at 0.3 and 1 mg/kg from day 12 to day 28 after primary 
administration. As shown in Fig. 11B, all 12 mice in the control group experienced the 
relapse of EAE from day 6 to day 16 after primary administration. FTY720 (0.03 to 1 mg/kg) 
significantly prolonged the time to confirm the relapse of EAE and no relapse was seen in 
group given FTY720 at 0.3 and 1 mg/kg, indicating an almost complete prevention for the 
relapse of EAE (Fig. 9B). 
 
 
Fig. 9. Therapeutic effects of FTY720 on EAE induced by PLP139-151 in SJL/J mice. SJL/J mice 
were immunized with PLP139-151 (50 μg/mouse) and Freund’s complete adjuvant. EAE-
developed mice were divided into 5 groups on day 15 day after immunization and 
administered vehicle or FTY720 orally every day for 28 days. (A) Clinical scores are 
expressed as the mean ± S.E.M. of 12 mice. Statistical differences in EAE scores were 
calculated by Steel’s test (*: p<0.05, **: p<0.01 versus vehicle-treated control group). (B) 
Results are expressed as the proportion of mice remaining relapse-free in total 12 mice. 
Statistical differences were calculated by generalized Wilcoxon test adjusted by Holm’s 
multiple comparison test (**: p<0.01 versus vehicle-treated control group). 
Next, we directly compared the therapeutic effects of FTY720 and rm-IFN-ǃ on relapsing-
remitting EAE induced by PLP139–151 in SJL/J mice. EAE-developed SJL/J mice were divided 
into 5 groups on day 15 after immunization and then administered vehicle, FTY720 (0.1 and 
0.3 mg/kg p.o., daily), or rm-IFN-ǃ (3000 and 10000 IU/mouse, subcutaneously every other 
day) for 28 days (Chiba et al. 2011). The relapse of EAE was markedly inhibited in groups 
given FTY720 at 0.1 and 0.3 mg/kg (Fig. 10A). The administration of rm-IFN-ǃ at low dose 
(3000 IU/mouse) resulted in only a slight but not significant inhibition on day 14 after 
primary administration. The high dose (10000 IU/mouse) of rm-IFN-ǃ showed a significant 
reduction of EAE scores, suggesting a delay of the relapse in early period of administration; 
however even high dose of rm-IFN-ǃ failed to prevent the relapse of EAE in latter period 
(Fig. 10B).  
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Fig. 10. Therapeutic effects of FTY720 and rm-IFN-ǃ on relapsing remitting EAE induced by 
PLP139-151 in SJL/J mice. EAE-developed mice were divided into 5 groups on day 15 after the 
immunization. Clinical scores are expressed as the mean ± S.E.M. of 12 mice. (A) Statistical 
differences in clinical scores of EAE were calculated by Steel’s test (*: p<0.05, **: p<0.01 
versus control). (B) Results are expressed as the proportion of mice remaining relapse-free in 
total 12 mice. Statistical differences were calculated by generalized Wilcoxon test adjusted 
by Holm’s multiple comparison test (**: p<0.01 versus vehicle-treated control, ##: p<0.01 
versus rm-IFN-ǃ 3,000 IU/mouse, †: p<0.05, ††: p<0.01 versus rm-IFN-ǃ 10,000 IU/mouse).  
All mice in the control group experienced the relapse of EAE from day 6 to day 14. FTY720 
at 0.1 and 0.3 mg/kg significantly prolonged the time to first confirmed relapse and no 
relapse was seen in 0.3 mg/kg group (Fig 10C). In the high dose of rm-IFN-ǃ group, the 
relapse of EAE was significantly delayed; however all mice given rm-IFN-ǃ experienced the 
relapse of EAE (Fig. 10D). Furthermore, FTY720 significantly prolonged the time to first 
confirmed relapse as compared with rm-IFN-ǃ, indicating that FTY720 shows a superior 
efficacy for preventing the relapse of EAE as compared with rm-IFN-ǃ. 
5.4 FTY720 reduces infiltration of Th17 cells and Th1 cells into the spinal cords of 
PLP-induced EAE in SJL/J mice 
To elucidate the effects of FTY720 on demyelination and infiltration of CD4+ T cells into the 
CNS in EAE induced by PLP139–151, the spinal cords were obtained from EAE mice given 
FTY720 or vehicle on day 28 after immunization.  
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Fig. 11. Effects of FTY720 on the frequency of PLP-specific Th1 and Th17 cells in the spinal 
cords and inguinal lymph nodes in EAE mice immunized with PLP139-151. SJL/J mice were 
immunized with PLP139-151 (50 μg/mouse) and Freund’s complete adjuvant. EAE-developed 
mice were administered FTY720 at an oral dose of 0.1 mg/kg therapeutically for 28 days. On 
the next day of the final administration, the spinal cords were obtained and were stained 
with H&E (A) control, (B) FTY720 0.1 mg/kg. Immunohistochemical staining of the spinal 
cords was performed by using anti-mouse CD4 mAb: (C) control, (D) FTY720 0.1 mg/kg. On 
the same day, lymphocytes were prepared from the spinal cords or inguinal lymph nodes of 
EAE mice and were cultured for 72 h in the presence of PLP139-151 (50 µg/ml). After the 
culture, intracellular cytokine staining was performed by using anti-mouse CD4, anti-mouse 
IL-17, and anti-mouse IFN-Ǆ mAbs (E).  
Demyelination and infiltration of inflammatory cells including lymphocytes were observed 
in the spinal cord of EAE mice in vehicle-treated control group (Fig. 11A). Therapeutic oral 
administration of FTY720 at 0.1 mg/kg resulted in a marked reduction of demyelination and 
infiltration of inflammatory cells in the spinal cord of EAE mice (Fig. 11B). By 
immunohistochemical staining using anti-mouse CD4 mAb, it was revealed that CD4+ T 
cells were infiltrated into the spinal cord, particularly the perivascular area and funiculus 
dorsalis in white matter under pia matter of EAE mice (Fig. 11C). Therapeutic 
administration of FTY720 at 0.1 mg/kg orally resulted in a marked reduction of infiltration 
of CD4+ T cells into the spinal cord (Fig. 11D). 
To clarify the involvement of myelin antigen-specific Th17 and Th1 cells, lymphocytes were 
prepared from the spinal cord and inguinal lymph nodes of EAE mice induced by 
immunization of PLP139–151 on day 28 after immunization (Chiba et al., 2011). The obtained 
lymphocytes were re-stimulated with PLP139–151 for 72 h in vitro. Then, the numbers of PLP-
specific Th17 cells and Th1 cells were determined by intracellular cytokine staining using 
anti-mouse CD4, anti-IL-17, and anti-IFN-Ǆ mAbs. Fig. 11E shows a typical pattern of 
intracellular cytokine staining of CD4-gated Th17 cells and Th1 cells in the spinal cord 
and inguinal lymph nodes in EAE mice. Significant numbers of Th17 and Th1 cells were 
found in the spinal cord from EAE mice, indicating the infiltration of myelin PLP-specific 
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Th17 and Th1 cells into the CNS of EAE mice. FTY720 (0.1 mg/kg) markedly reduced the 
infiltration of PLP-specific Th17 and Th1 cells into the spinal cord of EAE mice (Chiba et 
al., 2011). On the contrary, FTY720 increased the frequency of PLP-specific Th17 and Th1 
cells in inguinal lymph nodes to approximately 3-fold, suggesting inhibition of egress of 
PLP-specific Th cells from draining lymph nodes. From these results, therapeutic effects of 
FTY720 on EAE are likely due to reduction of infiltration of myelin antigen-specific Th 
cells into the CNS. 
6. Effects of FTY720 on MOG-induced EAE in C57BL/6 mice  
6.1 Prophylactic and therapeutic effects of FTY720 on MOG-induced EAE in C57BL/6 
mice  
When C57BL/6 mice were immunized with MOG35-55 in the presence of Freund’s complete 
adjuvant, chronic progressing EAE was developed on day 11 and reached a maximal level 
on day 17 after the immunization. Prophylactic administration of FTY720 at an oral dose of 
0.3 mg/kg resulted in a marked delay in the onset of EAE and a significant reduction of 
EAE symptoms during the administration period (Fig. 12A) (Seki et al, 2010). 
To examine the therapeutic effects of FTY720 on EAE induced by immunization with 
MOG35-55 in C57BL/6 mice, EAE-established mice were divided into 3 groups consisting of 
eleven mice 17 days after the immunization (Kataoka et al., 2005). When FTY720 (0.1 and 0.3 
mg/kg) was administered therapeutically, the symptoms of EAE were significantly 
improved during the administration period (Fig. 12B).  
 
 
 
Fig. 12. Prophylactic and therapeutic effects of FTY720 on MOG35-55-induced EAE in 
C57BL/6 mice. C57BL/6 mice were immunized with MOG35-55 (200 μg/mouse) in the 
presence of Freund’s complete adjuvant. (A) Prophylactic administration of FTY720 was 
stared on the day of the immunization for 21 days. (B) EAE-developed mice were pooled, 
divided into 3 groups and therapeutic administration of FTY720 was started from day 17 for 
25 days. Clinical scores are expressed as the mean ± S.E.M. of 10 to 11 mice. Statistical 
differences were calculated by Mann-Whitney U test (A) or Steel’s test (B) (*: p<0.05, **: 
p<0.01). 
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To compare the therapeutic effects of FTY720 and rm-IFN-ǃ on chronic EAE induced by 
MOG35-55 in C57BL/6 mice, EAE-developed mice were divided into 5 groups on day 15 after 
immunization with MOG35-55, and administered vehicle or FTY720 (oral doses of 0.03, 0.1, 
0.3 and 1 mg/kg) daily for 28 days (Chiba et al., 2011). Therapeutic administration of 
FTY720 at 0.1 to 1 mg/kg significantly improved the EAE-associated symptoms during 
administration period (Fig. 13A). On the other hand, rm-IFN-ǃ (subcutaneous injection at 
10,000 IU/mouse every other day) showed no clear effect on chronic EAE induced by 
MOG35-55 (Fig. 13B). 
6.2 FTY720 reduces infiltration of Th17 and Th1 cells into the spinal cords of EAE 
mice induced by immunization with MOG 
Demyelination and infiltration of inflammatory cells including lymphocytes were observed 
in the spinal cord of EAE mice in vehicle-treated control group (Fig. 14A). Therapeutic oral 
administration of FTY720 at 0.3 mg/kg resulted in a marked reduction of demyelination and 
infiltration of inflammatory cells in the spinal cord of EAE mice (Fig. 14B). By 
immunohistochemical staining using anti-mouse CD4 mAb, it was revealed that CD4+ T 
cells were infiltrated into the spinal cord of EAE mice (Fig. 14C). Therapeutic administration 
of FTY720 at 0.1 mg/kg orally resulted in a marked reduction of infiltration of CD4+ T cells 
into the spinal cord (Fig. 14D). 
To examine the influence of FTY720 on infiltration of Th17 and Th1 cells into the CNS in 
MOG35-55-induced EAE in C57BL/6 mice, the spinal cords were obtained from EAE mice 
 
 
 
Fig. 13. Therapeutic effects of FTY720 and rm-IFN-ǃ on chronic EAE induced by MOG35-55 in 
C57BL/6 mice. C57BL/6 mice were immunized with MOG35-55 (200 μg/mouse) and EAE-
developed mice were divided into 5 groups on day 14 after immunization. (A) FTY720 was 
administered orally every day for 28 days. (B) rm-IFN-ǃ was administered subcutaneously 
every other day for 28 days. Clinical scores are expressed as the mean ± S.E.M. of 12 mice. 
Statistical differences in EAE scores were calculated by Steel’s test (*: p<0.05, **: p<0.01 
versus control group). There was no significant difference between control group and rm-
IFN-ǃ-treated group by Wilcoxon test. 
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given FTY720 or vehicle for 16 days. Th17 and Th1 cells infiltrated into the spinal cords were 
determined by intracellular cytokine staining with mAbs against IL-17 and IFN-Ǆ. Fig. 14E 
shows a typical pattern of intracellular cytokine staining of CD4-gated IL-17-expressing 
Th17 cells and IFN-Ǆ-expressing Th1 cells in the lymphocytes infiltrated into the spinal 
cords in EAE mice (Seki et al., 2010). The number of CD4+ T cells infiltrated into the spinal 
cords was markedly decreased to less than 10% of control EAE mice by prophylactic 
administration of FTY720 at 0.3 mg/kg for 16 days. Moreover, the frequency of Th17 and 
Th1 cells in the spinal cords of EAE mice given FTY720 was also markedly decreased 
compared with control (Fig. 14E). On the contrary, the frequency of Th17 and Th1 cells in 
draining inguinal lymph nodes was increased to approximately 2-fold by the administration 
of FTY720, suggesting that myelin antigen-specific Th cells can not exit from draining lymph 
nodes into periphery by treatment with FTY720. 
FTY720-P, an active metabolite of FTY720, is known to show an agonistic activity on S1P 
receptors; however it acts as a functional antagonist of S1P1, because it strongly internalizes 
S1P1 receptor and reduces S1P responsiveness of lymphocytes (Brinkmann et al 2002, 2004; 
Chiba, 2005; Cyster, 2005; Maeda et al., 2007, Matloubian et al., 2004; Pham et al., 2008). As 
reported previously, mouse CD4+ T cells shows a migratory respond to a physiological 
concentration (10 nM) of S1P and the S1P responsiveness of CD4+ T cells is almost 
completely inhibited by pretreatment with 0.3 to 3 nM FTY720-P. To know whether myelin 
antigen-specific Th17 and Th1 cells generated in draining lymph nodes can respond a   
 
 
Fig. 14. Effects of FTY720 on the frequency of Th1 and Th17 cells in the spinal cords and 
inguinal lymph nodes in EAE mice immunized with MOG35-55. C57BL/6 mice were 
immunized with P MOG35-55 (200 μg/mouse) and EAE-developed mice were administered 
FTY720 at an oral dose of 0.1 mg/kg therapeutically for 28 days. On the next day of the final 
administration, the spinal cords were obtained and were stained with H&E (A) control, (B) 
FTY720 0.3 mg/kg. Immunohistochemical staining of the spinal cords was performed by 
using anti-mouse CD4 mAb: (C) control, (D) FTY720 0.3 mg/kg. On the same day, 
lymphocytes were prepared from the spinal cords or inguinal lymph nodes of EAE mice and 
intracellular cytokine staining was performed by using anti-mouse CD4, anti-mouse IL-17, 
and anti-mouse IFN-Ǆ mAbs (E).  
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physiological concentration of S1P, we performed migration assays toward S1P using 
lymphocytes from draining inguinal lymph nodes of EAE-established mice. Both Th17 and 
Th1 cells prepared from the draining lymph nodes of EAE mice could migrate toward 10 nM 
S1P and the migratory response of these Th cells toward S1P was almost completely inhibited 
by pretreatment with 1 nM of FTY720-P (Seki et al., 2010). On the other hand, FTY720-P up to 
100 nM showed no clear effect on the generation of either Th17 or Th1 cells from naïve CD4+ T 
cells in vitro (Seki et al., 2010). Moreover FTY720-P did not affect IL-17 production from Th17 
cells or IFN-Ǆ production from Th1 cells in vitro (Seki et al., 2010). From these results, it is 
suggested that FTY720-P converted from FTY720 inhibits egress of myelin antigen-specific 
Th17 and Th1 cells from draining lymph nodes, reduces infiltration of these Th cells into the 
CNS, and shows ameliorating effects on EAE in mice. 
7. Therapeutic effects of FTY720 in relapsing remitting MS  
The first clinical evidence that FTY720 has the therapeutic benefits in MS was provided in a 
6-month, placebo-controlled Phase II trial involving 281 patients with relapsing remitting 
MS (RRMS) (Kappos et al., 2006). Patients receiving FTY720 at an oral dose of 1.25 mg or 5.0 
mg daily had a significant lower median total number of gadolinium-enhancing lesions (the 
primary end point) on magnetic resonance imaging (MRI) than those receiving placebo. The 
annualized relapse rates in groups given 1.25 mg and 5.0 mg of FTY720 were 0.35 and 0.36, 
respectively and were significantly lower than that in the placebo group (0.77). By extension 
study for additional 6 months, the number of gadolinium-enhanced lesions and relapse 
rates remained low in groups given FTY720 and both measures decreased in patients who 
switched from placebo to FTY720. 
In FTY720-treated MS patients, the number of IL-17-expressing CD4+ T cells were reduced 
by >95% in the peripheral blood suggesting that FTY720 inhibits egress of Th17 cells from 
the SLO and reduces the infiltration of Th17 cells into the CNS (Brinkman, 2009; Mehling et 
al., 2010). In addition, FTY720 primarily reduced the numbers of CCR7+ CD45RA+ naïve T 
cells and CCR7+ CD45RA- central memory T cells in the blood in MS patients, because these 
T cells express the homing receptor CCR7, recirculate through the lymph nodes, and can be 
sequestered into the lymph nodes by FTY720. In contrast, CCR7- CD45RA- and CCR7- 
CD45RA+ effector memory T cell subsets are not sequestered into the SLO and are remained 
in the blood when FTY720 is administered. These results suggest that FTY720 effectively 
inhibits infiltration of pathogenic CD4+ T cells including Th 17 cells into the CNS in MS 
patients whereas FTY720 does not affect the function of effector memory T cells that play an 
important role in the prevention of infection. 
FTY720 was evaluated in a 24-month, double blind Phase III study (FREEDOMS study), 
involving 1272 patients RRMS (Kappos et al., 2010). The patients were randomized to 
receive a daily oral dose of FTY720 at 0.5 mg or 1.25 mg, or placebo. The annualized relapse 
rates in groups given 0.5 mg and 1.25 mg of FTY720 were 0.18 and 0.16, respectively and 
were significantly lower than that in the placebo group (0.40). FTY720 at 0.5 mg and 1.25 mg 
significantly reduced the risk of disability progression over 24-month period. The 
cumulative probability of disability progression confirmed after 3 months was 17.7% with 
0.5 mg FTY720, 16.6% with 1.25 mg FTY720, and 24.1% with placebo. FTY720 at 0.5 mg and 
1.25 mg showed improved effects compared with placebo with regard to the MRI-related 
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measures (number of new or enlarged lesions on T2-weightend images, gadolinium-
enhanced lesions, and brain-volume loss).  
FTY720 was also evaluated in a 12-month, double blind, double dummy Phase III study 
(TRANSFORMS study) involving 1292 patients with relapsing remitting MS, comparing 
FTY720 with IFN-ǃ-1a (AVONEX®), an established therapy for MS (Cohen et al., 2010). 
Patients were randomized to receive a daily dose of 0.5 mg or 1.25 mg FTY720 orally, or a 
weekly intramuscular injection of IFN-ǃ-1a. The annualized relapse rates in groups given 
FTY720 0.5 mg and 1.25 mg were 0.16 and 0.20 respectively, and were significantly lower 
than that in the group receiving IFN-ǃ-1a (0.33). FTY720 at 0.5 mg and 1.25 mg showed 
improved effects compared with IFN-ǃ-1a with regard to MRI-related measures. These 
Phase III studies demonstrated that oral FTY720 had superior efficacy compared with 
intramuscular IFN-ǃ-1a and placebo with regard to reducing the rate of relapse and MRI-
related measures of inflammatory lesion activity. Based on these results from clinical trials, 
FTY720 was approved by the United States Food and Drug Administration in September 
2010 as a first-line treatment for RRMS. As FTY720 has been approved more than 40 
countries including EU at this time, it is presumed that oral FTY720 provides a new 
therapeutic approach for RRMS. 
8. Conclusion  
FTY720, a S1P receptor modulator, acts as a functional antagonist at S1P1 and is highly 
effective in EAE in rats and mice. We directly compared the therapeutic effects of FTY720 
and rm-IFN-ǃ on relapse and progression of EAE in mice. When FTY720 at oral doses of 0.03 
to 1 mg/kg was administered daily after establishment of EAE induced by myelin PLP in 
SJL/J mice, relapse of EAE was significantly inhibited during administration period. 
Subcutaneous injection of rm-IFN-ǃ (10,000 IU/mouse) also inhibited the relapse of EAE at 
early period; however EAE was relapsed in all the mice within administration period. 
Therapeutic administration of FTY720 (0.03 to 1 mg/kg) significantly improved the 
symptoms of chronic EAE induced by myelin oligodendrocyte glycoprotein in C57BL/6 
mice whereas rm-IFN-ǃ (10,000 IU/mouse) showed no clear effect. These results indicate 
that FTY720 is more efficacious in mouse EAE as compared with rm-IFN-ǃ. FTY720 
markedly reduced the frequency of myelin antigen-specific Th17 and Th1 cells in the spinal 
cord of EAE mice, suggesting that the ameliorating effects of FTY720 on EAE are likely due 
to reduction of infiltration of myelin antigen-specific Th17 and Th1 cells into the CNS. 
Recently, it has been strongly suggested that FTY720-P directly acts as a functional 
antagonist at S1P1 on not only lymphocytes but also neural cells, particularly astrocytes  
because the therapeutic effects of FTY720 on EAE was lost in CNS mutants lacking S1P1 on 
astrocytes but not neuron. Since FTY720 possesses a completely new mechanism of action 
and shows superior efficacy compared with intramuscular IFN-ǃ-1a (AVONEX®) in 
relapsing remitting MS patients, FTY720 should be a useful therapeutic approach for MS. 
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